4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Immuron Limited (IMRN) operates in the Biotechnology industry and is headquartered in Carlton, Australia. Its market capitalization is roughly $15 million.
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Interactive charts & full statements → Open the IMRN valuation workbench →
| Income statement | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue | — | AUD 7M | AUD 5M | AUD 2M | AUD 1M |
| Gross Profit | — | AUD 5M | AUD 3M | AUD 1M | AUD 0M |
| Operating Income (EBIT) | — | (AUD 5M) | (AUD 5M) | (AUD 3M) | (AUD 3M) |
| Net Income | — | (AUD 5M) | (AUD 7M) | (AUD 4M) | (AUD 3M) |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Dividends Paid | AUD 0M | AUD 0M | AUD 0M | AUD 0M |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Assets | AUD 10M | AUD 16M | AUD 22M | AUD 25M |
| Total Liabilities | AUD 2M | AUD 3M | AUD 2M | AUD 2M |
AUD; AUDM / AUDB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IMRN viewer.
About TickerBase · Data methodology & sources · Privacy · Terms